Assertio Holdings

Assertio has postponed the start of Garda’s takeover offer for all outstanding shares to May 14, 2026, and has simultaneously moved the start of a separate offer for all outstanding convertible senior notes to the same date. Under the amended acquisition agreement, Garda has acquired Assertio for $21.80 per share, with total consideration of $153.2 million. The stock is trading at $22.37, slightly above the offer price; a Schedule 14D-9 is expected to be filed on May 14. » More on de.investing.com

In coordination with Garda Therapeutics, Assertio has postponed the start of the announced takeover offer to May 8, 2026. Garda is offering $21.80 per share in cash, with total consideration of $153.2 million; the stock is trading close to that price with an arbitrage spread below 1%. Assertio will file a Schedule 14D-9 on May 8 and is also postponing the offer for outstanding convertible senior notes; upon closing, Assertio will become a 100% subsidiary of Garda. » More on de.investing.com

Assertio’s stock rose 16% after Garda Therapeutics raised its cash offer to $21.80 per share. The new offer corresponds to a premium of 21.1% over Garda’s original bid and 63.1% over the March 20, 2026 price, valuing Assertio at $153.2 million. The increased consideration is secured by committed equity and debt financing and was deemed advantageous for shareholders by the board. The closing is expected in the second quarter of 2026, includes no contingent value right, and, after successful tendering, foresees a second-step merger and the delisting of Assertio from NASDAQ. » More on de.investing.com